Dr. Anuj Jayakar, MD
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
At a glance
- In the NPI registry since
- 2012
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
FL license ME131903
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 14 companies reported 75 payments worth $6,506 in total to this clinician.
| Neurelis, Inc. | $4,515 |
|---|---|
| Jazz Pharmaceuticals Inc. | $875 |
| UCB, Inc. | $686 |
| Corium, LLC | $72.95 |
| Catalyst Pharmaceuticals, Inc. | $59.49 |
| Biocodex, Inc. | $53.56 |
| Aucta Pharmaceuticals, Inc. | $45.95 |
| Upsher-smith Laboratories LLC | $45.86 |
| Consulting Fee | $4,293 |
|---|---|
| Food and Beverage | $2,213 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Neurelis, Inc. Jan 23, 2025 | Consulting Fee VALTOCO · EPILEPSY | $4,293 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $102,892 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
UCB SA · Completed · NCT04666610 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
UCB SA · Terminated · NCT04519645 - A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
UCB SA · Active, not recruiting · NCT06315322
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.